Home / Technology & Devices (page 40)

Technology & Devices

Registration Open for Biosimilars 20/20: The Next Five Years

TAMPA, FL, April 1, 2015 – The Specialty Pharma Education Center (SPEC) and Specialty Pharma Journal (SPJ) today announced that registration is now open for Biosimilars 20/20, scheduled for June 3-4, 2015 at The Hub in Philadelphia, PA. Biosimilars 20/20 promises to provide an in-depth look into the future of the …

Read More »

Fujifilm to Acquire Stem Cell Pioneer Cellular Dynamics for $307 Million

Japan’s Fujifilm said that it will pay more than $300 million for Wisconsin-based stem cell developer Cellular Dynamics International (CDI) to strengthen its presence in the regenerative field. The companies announced that they have entered into a definitive agreement, under which Fujifilm will acquire CDI. Fujifilm aims to acquire all …

Read More »

Teva Strengthens its CNS Portfolio with its $3.2 Billion Acquisition of Auspex

Today, Teva Pharmaceutical Industries Ltd. announced that it has agreed to acquire central nervous system (CNS) drug developer Auspex Pharmaceuticals, Inc. for about $3.2 billion. The companies said that they have entered into a definitive merger agreement, under which Teva will commence a tender offer for all of the outstanding …

Read More »

Novartis Enters $750 Million Immuno-Oncology Collaboration with Aduro Biotech

Swiss drugmaker Novartis is increasing its efforts in immuno-oncology, entering a $750 million research, development and commercialization agreement with Aduro Biotech, Inc. The companies announced a collaboration for the worldwide research, development and commercialization of novel immuno-oncology products derived from Aduro’s cyclic dinucleotide (CDN) approach to target the Stimulator of …

Read More »

NCPDP Work Group Seeks Solutions in Response to OIG’s Study on Coupon and Copay Violations

In an effort to address concerns regarding pharmaceutical manufacturers’ coupon and copayment programs and the resulting costs to federal government health programs, the National Council for Prescription Drug Programs’ (NCPDP) task group is pulling together clear guidance around the OIG guidelines. The task group is looking at a variety of …

Read More »

RXi and MirImmune Enter Licensing Deal for RXi’s Technology for Development of Cell-Based Cancer Immunotherapies

RXi Pharmaceuticals and privately-held MirImmune have entered into a license agreement to use RXi’s novel and proprietary technology for development of cell-based cancer drugs. The companies announced that they have entered into an exclusive license agreement to RXi’s sd-rxRNA technology for use in developing innovative cell-based cancer immunotherapies. The collaboration …

Read More »

Amgen’s deCODE Genetics Study Reveals Clues to Disease-Causing Genes

Amgen’s deCODE Genetics published four landmark papers built on whole-genome sequence data from more than 100,000 people from across Iceland. Research groups led by scientists from Amgen’s deCODE Genetics reported data that comprise the largest set of human genome sequenced from a single population in Nature Genetics. Four separate papers …

Read More »

AstraZeneca and Harvard Stem Cell Institute Team Up for Diabetes Research

AstraZeneca inked a five-year research deal with Harvard Stem Cell Institute (HSCI) for new treatments for diabetes. The company announced today that it has entered into a five-year research collaboration with HSCI to adapt a technique that creates human beta cells from stem cells for use in screens for AstraZeneca’s …

Read More »

Semma Secures $44 Million and Partners with Novartis for Diabetes Stem Cell Therapy

New diabetes biotech startup, working on a stem cell technology that could potentially reverse the cause of Type 1 diabetes, has picked up $44 million in funding, and entered into a deal with Novartis Pharmaceuticals. Semma Therapeutics announced Tuesday that it has closed a $44 million Series A consisting of …

Read More »

Cypher Genomics’ New Technology Addresses Major Obstacle in Personalized Medicine for Cancer

A major bottleneck for realizing personalized medicine in cancer is understanding the clinical importance of tumor-specific genomic alterations, according to genome informatics company, Cypher Genomics, Inc. In an effort to address this challenge, the San Diego-based company announced that it has released a new software update to automate the interpretation …

Read More »